Stay informed with free updates
Simply sign up to the Pharmaceuticals sector myFT Digest — delivered directly to your inbox.
Pfizer’s oncology chief has warned that the Biden administration’s drug price reforms could hurt the development of cancer treatments targeted at children or patients suffering from rarer forms of the disease.
In August, the US government unveiled $7.5bn of cost savings for taxpayers from the first 10 drugs eligible for price negotiations with Medicare, the…
Read the full article here